A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency

Inclusion Criteria:

• Bone age less than equal to (</=) 9 years (females) or </= 11 years (males) asdetermined by X-ray of the left hand and wrist using Greulich and Pyle method andobtained within the 12 months prior to enrollment

• Prepubertal (Tanner I) males and females by physical examination

• Diagnosis of GHD (stimulated GH less than [<] 10 nanograms per milliliter [ng/mL]) bytwo standard pharmacologic tests obtained up to 12 months prior to informedconsent/assent

• Normal thyroid function test within the 12 months prior to informed consent/assent

• Normal complete blood counts within 12 months prior to informed consent/assent

• Documentation of prior height and weight measurements, with height standard deviationscore (SDS) </= 5th percentile for idiopathic isolated GHD participants

Exclusion Criteria:

• Any previous rhGH treatment

• Short stature etiologies other than GHD

• Acute critical illness or uncontrolled chronic illness, which in the opinion of theinvestigator and medical monitor, would interfere with participation in this study,interpretation of the data, or pose a risk to participant safety

• Chronic illnesses such as inflammatory bowel disease, celiac disease, heart disease,and diabetes

• Bone diseases such as achondroplasia or hypochondroplasia, intracranial tumor,irradiation, and traumatic brain injury

• Participants receiving oral or inhaled chronic corticosteroid therapy (greater than [>] 3 months) for other medical conditions other than central adrenal insufficiency

• Participants who require higher (2 times or greater than maintenance) doses ofcorticosteroids for more than 5 days in the 6 months prior to enrollment in the study

• Participants with active malignancy or any other condition that the investigatorbelieves would pose a significant hazard to the participant if rhGH were initiated

• Females with Turner syndrome regardless of their GH status

• Prader-Willi syndrome regardless of GH status

• Born small for gestational age regardless of GH status

• Presence of scoliosis requiring monitoring

• Previous participation in another clinical trial or investigation of GH, treatment forgrowth failure, or treatment with a biologic agent

• Participants with closed epiphyses

• Participants with a known hypersensitivity to somatropin, excipients, or diluent